Study Stopped
Study was terminated due to inability of clinical site to enroll sufficient number of subjects
Comparison of Non-invasive Vs. Invasive Hemodynamic Measurements
Comparison Study of EzCVP and CVP
1 other identifier
observational
8
1 country
1
Brief Summary
Comparison of a non-invasive method of measuring central venous pressure to the conventional modality of invasive central venous pressure.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jan 2020
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 25, 2019
CompletedFirst Posted
Study publicly available on registry
November 27, 2019
CompletedStudy Start
First participant enrolled
January 16, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 20, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
June 20, 2022
CompletedDecember 27, 2024
December 1, 2024
2.4 years
November 25, 2019
December 21, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Non-invasive pressure indicator
Evaluate sensitivity and specificity of ezCVP indication based on the case where CVP is in a 'low range' (0 \< CVP \< 10 mmHg) or 'high range' (\>= 10 mmHg)
12-72 hours
Secondary Outcomes (2)
Direction of change
12-72 hours
Correlation with invasive CVP
12-72 hours
Interventions
Non-invasive method to measure central venous pressure indicator
Eligibility Criteria
Patients admitted to the El Camino Hospital ICU with central venous catheter.
You may qualify if:
- Adult age over 18 years.
- Arm circumference is 23 cm to 55 cm
- Subject will have an existing central venous catheter during their ICU stay
- Subject or legally authorized representative (LAR) is able to understand the risks and potential benefits of participating in the study and is willing to provide written informed consent
- Subject or LAR is willing and able to comply with protocol procedures
You may not qualify if:
- Finger and/or upper arm anatomical anomaly or disease that may interfere with attaching a pulse oximeter sensor and/or blood pressure cuff.
- Pregnant (self-reported)
- Upper extremity deep venous thrombosis currently being treated
- Severe skin disease involving the upper arm(s)
- Study investigator may exclude patients based on clinical judgement
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Nihon Kohdenlead
Study Sites (1)
El Camino Hospital
Mountain View, California, 94040, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Zachary Edmonds, MD
Palo Alto Foundation Medical Group
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 25, 2019
First Posted
November 27, 2019
Study Start
January 16, 2020
Primary Completion
June 20, 2022
Study Completion
June 20, 2022
Last Updated
December 27, 2024
Record last verified: 2024-12
Data Sharing
- IPD Sharing
- Will not share
Only summary data of participants will be shared.